Search
MK-0354
go.drugbank.com/drugs/DB05939InvestigationalMK-0354, is an orally administered drug candidate under development by Merck for the treatment of atherosclerosis and related disorders.
Pipendoxifene
go.drugbank.com/drugs/DB05414InvestigationalPipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment … ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer.
4'-Methylene-5,8,10-trideazaaminopterin
go.drugbank.com/drugs/DB05616InvestigationalCH-1504 is a an antirheumatic agent that has been shown in vitro to be a nonpolyglutamylatable and nonhydroxylatable antifolate that is more efficiently taken up into cells by the reduced folate carrier
beta-Alanine
go.drugbank.com/drugs/DB03107InvestigationalA rare genetic disorder, hyper-beta-alaninemia, has been reported. … beta-Alanine is an amino acid formed in vivo by the degradation of [dihydrouracil] and [carnosine].
19-norandrostenedione
go.drugbank.com/drugs/DB01434ExperimentalIllicitAfter 2005, 19-Norandrostenedione was regulated in the United States as a schedule III controlled substance, as well as banned from use in competitive sports by the World Anti-Doping Agency.
Placental Mesenchymal Stem Cells
go.drugbank.com/drugs/DB15730InvestigationalThe placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs).
CNS-5161
go.drugbank.com/drugs/DB05824ExperimentalCNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.
Faxeladol
go.drugbank.com/drugs/DB20529InvestigationalFaxeladol has a monoisotopic molecular weight of 233.18 Da. … Faxeladol is a small molecule drug. The usage of the INN stem '-adol/-adol-' in the name indicates that Faxeladol is a analgesic.
SAR445136
go.drugbank.com/drugs/DB17708InvestigationalSAR445136 is an investigational zinc finger nuclease gene-edited cell therapy.
MVC-COV1901
go.drugbank.com/drugs/DB15854InvestigationalMVC-COV1901 is a vaccine candidate developed and commercialized by Medigen Vaccine Biologics Corporation. The vaccine candidate contains a perfusion form of the SARS-Cov2 recombinant spike protein. … Medigen has combined forces with Dynavax, which offers an advanced adjuvant, CpG 1018 (also known as [ISS-1018]), for use with its vaccine.